Ask AI
ProCE Banner Activity

Optimizing Outcomes With Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Best Practices for Oncology Pharmacists

Slideset

Downloadable slides on best practices for anti-CD38–based treatments for smoldering and newly diagnosed multiple myeloma, including risk stratification, emerging clinical trial data, and transplant-eligible therapy approaches.

Released: May 13, 2026

Continue Activity

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by educational grants from Johnson & Johnson and Sanofi Genzyme.

Johnson & Johnson

Sanofi Genzyme

Target Audience

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with high-risk smoldering or newly diagnosed multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients with high-risk smoldering MM on the latest evidence and expert guidance on anti-CD38–based treatment to support informed shared decision-making

  • Recommend individualized treatment strategies leveraging anti-CD38–based quadruplets for appropriate patients with newly diagnosed symptomatic MM based on the latest clinical evidence, expert recommendations, and patient/disease factors

  • Apply pharmacist-led strategies to mitigate and manage adverse events related to anti-CD38–based treatments for MM